JavaScript is disabled. Please enable to continue!
Print this page

Save this page as a PDF

Mobile search icon
Menu
About Us >> Our Business >> Eurofins Fact Sheet
Search >>

Eurofins Fact Sheet

Sidebar Image

Company overview

Eurofins is Testing for Life. The Eurofins network of companies believes that it is a global leader in food, environment, pharmaceutical and cosmetic product testing and in discovery pharmacology, forensics, advanced material sciences and agroscience contract research services. It is also one of the market leaders in certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in biopharma contract development and manufacturing. It also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.

History

Eurofins Scientific was founded in 1987 with 3 employees and 1 laboratory to market a patented analytical method used to verify the origin and purity of several types of food and beverages and identify sophisticated fraud not detectable by other methods.

Today, the Eurofins Group is a leading provider of testing and analytical services with:

  • an international network of more than 950 laboratories in over 1,000 companies and 60 countries
  • ca. 63,000 staff
  • a portfolio of over 200,000 analytical methods
  • more than 450 million tests performed each year

2024 marked 27 years since Eurofins’ IPO on the Paris stock exchange on the 24th October 1997. On September 17th, 2021, Eurofins joined the CAC 40 index and has been, for almost three decades, one of the fastest growing listed European companies. Since its IPO, Eurofins’ revenues have increased by 29% each year (in compound average) to reach €7.0 billion in 2024. Furthermore, in the 27 years since its IPO to December 31st  2024, Eurofins has delivered a remarkable total shareholder return (reflecting both share price appreciation and reinvestment of dividends) of around 28,500%, equivalent to a compounded annual growth rate (CAGR) of over 23%. Among all companies with listings in major European exchanges over the 1997-2022 period analysed by a research firm, Eurofins ranked highest in terms of total shareholder return.

A commitment to innovation and sustainability

Since its foundation, Eurofins has contributed significantly to the advancement of science through Testing for Life. We are proud of the discoveries our specialists have made in a broad range of sectors, from food to pharma or forensics testing. Our laboratories around the world are helping to improve cancer treatments, catch criminals, safeguard the health of bees, ensure our food and water is safe, indicate paternity, protect transplant patients’ lives and combat viruses. Whether we are helping to improve health outcomes, ensure food safety or determine environmental impact, sustainability is at the heart of our work. To serve this purpose, Eurofins Sustainability Solutions brings together a wide range of Eurofins companies’ market-leading sustainability offerings and solutions in one place, to enable corporations, organisations and governments to contribute to product and enterprise sustainability. On the ground, we are working to become carbon neutral by 2025 through reduction and offsetting of carbon emissions. In 2023, Eurofins’ absolute carbon emissions declined by 8% vs 2022. In terms of carbon intensity relative to revenues, we are now 28% below the 2019 level. Eurofins has also committed to setting near-term science-based emission reduction targets in line with the Science Based Targets initiative (SBTi) Criteria and Recommendations. Lastly, the Eurofins Foundation supports charities and NGOs across the world, who share our goal of making the world a safer and healthier place for all.

Recent developments

In an operating environment characterised in some markets by more challenging and volatile conditions, Eurofins delivered a record level of revenues and solid overall results in line with its revenues and profitability objectives and considerably above its objective for free cash flow in spite of organic growth being slightly lower than its long-term averages in 2024 due to slowness of some of its ancillary BioPharma markets representing less than 10% of Group revenues. At €6.95bn, revenues in 2024 exceeded Eurofins’ peak COVID-19 pandemic-driven revenue level of €6.7bn achieved in 2021 and 2022.

Eurofins, through its activities, also continues to make meaningful contributions to Testing for Life. Eurofins Discovery’s SH2scan™ assay, developed using gold standard KINOMEscan® technology, quantitatively measures selective binding of test compounds to investigate historically undruggable targets or to evade resistance to existing therapeutic classes. Eurofins Viracor’s NeXGen™, a first-of-its-kind next generation sequencing assay for the detection of fungal pathogens and acid-fast bacteria, offers a powerful and comprehensive approach to infectious disease testing, providing clinicians with valuable insights on prominent pathogens allowing for more accurate diagnosis and appropriate treatment decisions. Eurofins On Farm Solutions, a service providing real-time insight into forage nutritional quality, was launched by Eurofins Agro Testing in a collaboration with trinamiX. Powered by the largest international forage analysis database, analysis performed by the Eurofins Forage Analysis App allows forage growing and feeding systems to be optimised, leading to improved animal health, boosted farm productivity and reduced environmental impact.

Outlook

Though the immediate macroeconomic outlook remains uncertain, Eurofins remains very confident in the long-term resilience and promising growth potential of its life-science and biopharma related markets. It also remains very confident in the strength of its leaders and employees, as well as its strategy to expand market and technological leadership, and to create commercial value for customers, financial value for investors and opportunities for its employees as it further progresses towards achieving its 2027 objectives, when Eurofins plans to have completed the buildout of a high growth, high margin, high returns and high cash flow Group leading key global life sciences markets which enjoy strong secular growth prospects.